Seroatlas · Human Serome Atlas

NFKB2

Nuclear factor NF-kappa-B p100 subunit

Also known as: LYT-10, NF-kB2, NFKB2_HUMAN, p105, p49/p100, p52

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q00653
Gene: NFKB2
Ensembl: ENSG00000077150
Chromosome: 10
Canonical length: 900 aa
Protein class: Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Transcription factors
Subcellular location: Nucleoplasm,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene encodes a subunit of the transcription factor complex nuclear factor-kappa-B (NFkB). The NFkB complex is expressed in numerous cell types and functions as a central activator of genes involved in inflammation and immune function. The protein encoded by this gene can function as both a transcriptional activator or repressor depending on its dimerization partner. The p100 full-length protein is co-translationally processed into a p52 active form. Chromosomal rearrangements and translocations of this locus have been observed in B cell lymphomas, some of which may result in the formation of fusion proteins. There is a pseudogene for this gene on chromosome 18. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2013]

Canonical amino-acid sequenceUniProt

900 residues, UniProt reviewed canonical sequence.

>Q00653|NFKB2
     1  MESCYNPGLD GIIEYDDFKL NSSIVEPKEP APETADGPYL VIVEQPKQRG FRFRYGCEGP
    61  SHGGLPGASS EKGRKTYPTV KICNYEGPAK IEVDLVTHSD PPRAHAHSLV GKQCSELGIC
   121  AVSVGPKDMT AQFNNLGVLH VTKKNMMGTM IQKLQRQRLR SRPQGLTEAE QRELEQEAKE
   181  LKKVMDLSIV RLRFSAFLRA SDGSFSLPLK PVISQPIHDS KSPGASNLKI SRMDKTAGSV
   241  RGGDEVYLLC DKVQKDDIEV RFYEDDENGW QAFGDFSPTD VHKQYAIVFR TPPYHKMKIE
   301  RPVTVFLQLK RKRGGDVSDS KQFTYYPLVE DKEEVQRKRR KALPTFSQPF GGGSHMGGGS
   361  GGAAGGYGGA GGGGSLGFFP SSLAYSPYQS GAGPMGCYPG GGGGAQMAAT VPSRDSGEEA
   421  AEPSAPSRTP QCEPQAPEML QRAREYNARL FGLAQRSARA LLDYGVTADA RALLAGQRHL
   481  LTAQDENGDT PLHLAIIHGQ TSVIEQIVYV IHHAQDLGVV NLTNHLHQTP LHLAVITGQT
   541  SVVSFLLRVG ADPALLDRHG DSAMHLALRA GAGAPELLRA LLQSGAPAVP QLLHMPDFEG
   601  LYPVHLAVRA RSPECLDLLV DSGAEVEATE RQGGRTALHL ATEMEELGLV THLVTKLRAN
   661  VNARTFAGNT PLHLAAGLGY PTLTRLLLKA GADIHAENEE PLCPLPSPPT SDSDSDSEGP
   721  EKDTRSSFRG HTPLDLTCST KVKTLLLNAA QNTMEPPLTP PSPAGPGLSL GDTALQNLEQ
   781  LLDGPEAQGS WAELAERLGL RSLVDTYRQT TSPSGSLLRS YELAGGDLAG LLEALSDMGL
   841  EEGVRLLRGP ETRDKLPSTA EVKEDSAYGS QSVEQEAEKL GPPPEPPGGL CHGHPQPQVH

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NFKB2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 48 nTPM

Expression across tissuesHPA

Tissue

spleen: 48 nTPM
lung: 40 nTPM
colon: 38 nTPM
kidney: 27 nTPM
prostate: 27 nTPM
liver: 26 nTPM

Single-cell type

neutrophils: 259 nCPM
oocytes: 101 nCPM
mast cells: 93 nCPM
pancreatic duct cells: 84 nCPM
monocytes: 81 nCPM
cdc: 73 nCPM

Immune cell

neutrophil: 2.9 nTPM
non-classical monocyte: 1.5 nTPM
naive B-cell: 1.2 nTPM
memory B-cell: 1.1 nTPM
classical monocyte: 0.7 nTPM
intermediate monocyte: 0.5 nTPM

Brain region

medulla oblongata: 7.6 nTPM
thalamus: 7.1 nTPM
pons: 6.5 nTPM
choroid plexus: 6.3 nTPM
white matter: 6.2 nTPM
cerebral cortex: 6.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NFKB2.

Disease | AllUniProt

Conditions NFKB2 is implicated in, by any mechanism.

Immunodeficiency, common variable, 10 (CVID10) MIM:615577

Disease | GeneticClinVar

18 pathogenic / likely-pathogenic of 887 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Immunodeficiency, common variable, 10
Inherited Immunodeficiency Diseases
Immunodeficiency, common variable, 1
NFKB2-related disorder

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.16
gnomAD pLI: 1
gnomAD missense Z: 3.94
DepMap mean gene effect: -0.09
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NFKB2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NFKB2 as an antibody target. Whether an autoantibody or antibody against NFKB2 could matter depends on whether native NFKB2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NFKB2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NFKB2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...